

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM480335

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Innovatus Life Sciences Lending Fund I, L.P.		07/03/2018	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Metabolon, Inc.		
Street Address:	617 Davis Drive		
Internal Address:	Suite 100		
City:	Morrisville		
State/Country:	NORTH CAROLINA		
Postal Code:	27560		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 11			
Property Type	Number	Word Mark	
Registration Number:	4746986	LIPOMICS	
Registration Number:	4727737		
Serial Number:	87438891	PRECISION METABOLOMICS	
Serial Number:	87192130	META IMD	
Registration Number:	3058960	METABOLON	
Registration Number:	3530800	METABOLON	
Registration Number:	4814724	METABOLON	
Registration Number:	4801218	METABOLYNC	
Registration Number:	4956087	QUANTOSE	
Registration Number:	4727739	TRUEMASS	
Serial Number:	87348647	ACCUGFR	
CORRESPONDENCE DATA			
Fax Number:	3102843894		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	3102843861		
Email:	d'arcy.conrique@btlaw.com		
Correspondent Name:	D'Arcy Conrique c/o Barnes & Thornburg		

OP \$290.00 4746986

Address Line 1: 2029 Century Park East, Suite 300
Address Line 4: Los Angeles, CALIFORNIA 90067

NAME OF SUBMITTER: DArcy Conrique

SIGNATURE: /DArcy Conrique/

DATE SIGNED: 07/03/2018

Total Attachments: 16

source=B04 IP Security Agreement Metabolon [exe with scheds]#page1.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page2.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page3.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page4.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page5.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page6.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page7.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page8.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page9.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page10.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page11.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page12.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page13.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page14.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page15.tif
source=B04 IP Security Agreement Metabolon [exe with scheds]#page16.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of the Effective Date by and between INNOVATUS LIFE SCIENCES LENDING FUND I, LP, as collateral agent for the Lenders (the "Lenders") described in the Loan Agreement (in such capacity, the "Collateral Agent") and METABOLON, INC. ("Grantor").

RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Collateral Agent, the Lenders and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks and Patents, to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

METABOLON, INC.

617 Davis Drive, Ste 100
Morrisville, NC 27560

By: 

Title: President and Chief Executive Officer

COLLATERAL AGENT:

Address of Lender:

INNOVATUS LIFE SCIENCES LENDING FUND
I, LP

777 Third Avenue, 25th Floor
New York, NY 10017

By: _____

Title: _____

[Signature Page to Intellectual Property Security Agreement]
[Metabolon, Inc.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

METABOLON, INC.

617 Davis Drive, Ste 100
Morrisville, NC 27560

By: _____

Title: _____

COLLATERAL AGENT:

Address of Lender:

INNOVATUS LIFE SCIENCES LENDING FUND
I, LP

777 Third Avenue, 25th Floor
New York, NY 10017

By: _____

Title: _____

[Signature Page to Intellectual Property Security Agreement]
[Metabolon, Inc.]

EXHIBIT A

Copyrights

SEE ATTACHED

Software not registered with the U.S. Copyright Office:

Software System	Purpose
Mlims	Laboratory information management system
Surveyor Tools	User interface for lipid data analysis

Licensing and Collaboration Agreements:

1. Laboratory Services Agreement effective July 1, 2014 with Baylor College of Medicine
2. Joint Laboratory Licensing Agreement effective December 30, 2016 with Zhejiang Dian Diagnostics Co., Ltd
3. Joint Laboratory Collaboration Agreement effective April 1, 2017 with Anti Doping Lab Qatar
4. Joint Laboratory Collaboration Agreement dated January 24, 2011 with the Helmholtz Zentrum Munchen – German Research Center for Environmental Health
5. Commercial License Agreement effective January 8, 2014 with Patia Biopharma S.A. de C.V.
6. Research and Collaboration Agreement effective January 8, 2014 with Patia Biopharma S.A. de C.V.
7. License Agreement dated July 21, 2003 with Cornell Research Foundation, Inc.
8. Non-Exclusive “Know-How” License Agreement dated June 2, 2016 with The Johns Hopkins University and Tufts Medical Center, Inc.
9. Collaboration Agreement dated May 12, 2016 with The Johns Hopkins University and Tufts Medical Center, Inc.
10. Settlement and License Agreement dated July 19, 2013 with Stemina Biomarker Discovery
11. Patent Purchase Agreement dated June 28, 2013 with Tethys Bioscience, Inc.
12. Cooperation Agreement dated January 7, 2016 with Labco
13. Collaboration Agreement dated January 18, 2011 with Eastern Virginia Medical School
14. Collaboration Agreement dated May 12, 2014 with Duke University

EXHIBIT B

Patents

SEE ATTACHED

Patents:

Applicant / Owner	Country	Application No.	Status	Filing Date	Patent No.	Issue Date	Expiration Date
Metabolon	US	10/300,360	Granted	11/20/2002	US 6,873,914	3/29/2005	12/7/2022
Metabolon/ Cornell	US	10/695,265	Granted	10/27/2003	US 7,329,489	2/12/2008	4/13/2021
Metabolon/ Cornell	US	10/757,616	Granted	1/13/2004	US 7,005,255	2/28/2006	4/13/2021
Metabolon	US	11/016,612	Granted	12/17/2004	US 8,428,881	4/23/2013	10/19/2029
Metabolon	US	11/133,953	Granted	5/20/2005	US 8,131,473	3/6/2012	11/23/2028
Metabolon	US	11/192,804	Granted	7/29/2005	US 8,594,942	11/26/2013	2/20/2030
Metabolon/ Cornell	US	11/301,077	Granted	12/12/2005	US 7,682,783	3/23/2010	4/13/2021
Metabolon/ Cornell	US	11/301,079	Granted	12/12/2005	US 7,682,784	3/23/2010	4/13/2021
Metabolon/ Cornell	US	11/357,732	Granted	2/17/2006	US 7,635,556	12/22/2009	4/13/2021
Metabolon/ Cornell	US	11/405,033	Granted	4/14/2006	US 7,550,258	6/23/2009	4/13/2021
Metabolon	CA	2618123.0	Granted	8/7/2006	CA 2,618,123	4/2/2013	8/7/2026
Metabolon	JP	2008-526121	Granted	8/7/2006	JP 4,950,993	3/16/2012	8/7/2026
Metabolon	US	11/462,838	Granted	8/7/2006	US 7,433,787	10/7/2008	8/7/2026
Metabolon	US	11/711,518	Granted	2/27/2007	US 8,841,077	9/23/2014	1/10/1930
Metabolon	CA	2646890.0	Granted	3/20/2007	CA 2,646,890	7/31/2012	3/20/2027
Metabolon	JP	2009-501695	Granted	3/20/2007	JP 5,496,650	3/14/2014	3/20/2027
Metabolon	US	11/688,526	Granted	3/20/2007	US 7,561,975	7/14/2009	11/12/2027
Metabolon/ Cornell	US	11/728,826	Granted	3/27/2007	US 7,910,301	3/22/2011	4/13/2021
Metabolon/ Cornell	US	11/728,827	Granted	3/27/2007	US 7,550,260	6/23/2009	4/13/2021
Metabolon/ Cornell	US	11/728,640	Granted	3/27/2007	US 7,553,616	6/30/2009	4/13/2021
Metabolon	CH	20070836680.0	Validated	8/8/2007	CH 2057473	11/12/2014	8/8/2027
Metabolon	DE	20070836680.0	Validated	8/8/2007	DE 2057473	11/12/2014	8/8/2027
Metabolon	EP	7836680.4	Granted	8/8/2007	EP 2057473	11/12/2014	8/8/2027
Metabolon	ES	20070836680.0	Validated	8/8/2007	ES 2057473	11/12/2014	8/8/2027
Metabolon	FR	20070836680.0	Validated	8/8/2007	FR 2057473	11/12/2014	8/8/2027
Metabolon	GB	20070836680.0	Validated	8/8/2007	GB 2057473	11/12/2014	8/8/2027
Metabolon	US	11/840,466	Granted	8/17/2007	US 7,807,138	10/5/2010	9/20/2027
Metabolon	US	11/901,523	Granted	9/17/2007	US 8,849,577	9/30/2014	4/6/1930
Metabolon	AU	2007299846.0	Granted	9/18/2007	AU 2007299846	3/5/2015	9/18/2027
Metabolon	CH	7868439.6	Validated	10/12/2007	EP 2,089,539	12/7/2011	10/12/2027
Metabolon	DE	7868439.6	Validated	10/12/2007	EP 2,089,539	12/7/2011	10/12/2027
Metabolon	EP	7868439.6	Granted	10/12/2007	EP 2,089,539	12/7/2011	10/12/2027
Metabolon	FR	7868439.6	Validated	10/12/2007	EP 2,089,539	12/7/2011	10/12/2027
Metabolon	GB	7868439.6	Validated	10/12/2007	EP 2,089,539	12/7/2011	10/12/2027
Metabolon	IE	7868439.6	Validated	10/12/2007	EP 2,089,539	12/7/2011	10/12/2027

Applicant / Owner	Country	Application No.	Status	Filing Date	Parent No.	Issue Date	Expiration Date
Metabolon	US	11/871,752	Granted	10/12/2007	US 7,781,160	8/24/2010	10/12/2027
Metabolon	US	12/218,980	Granted	7/17/2008	US 8,187,830	5/29/2012	7/26/2028
Metabolon	US	12/245,862	Granted	10/6/2008	US 7,949,475	5/24/2011	8/25/2029
Metabolon	CH	8845659.5	Validated	10/31/2008	EP 2,227,689	12/26/2012	10/31/2028
Metabolon	DE	8845659.5	Validated	10/31/2008	EP 2,227,689	12/26/2012	10/31/2028
Metabolon	EP	8845659.5	Granted	10/31/2008	EP 2,227,689	12/26/2012	10/31/2028
Metabolon	ES	8845659.5	Validated	10/31/2008	EP 2,227,689	12/26/2012	10/31/2028
Metabolon	FR	8845659.5	Validated	10/31/2008	EP 2,227,689	12/26/2012	10/31/2028
Metabolon	GB	8845659.5	Validated	10/31/2008	EP 2,227,689	12/26/2012	10/31/2028
Metabolon	IE	8845659.5	Validated	10/31/2008	EP 2,227,689	12/26/2012	10/31/2028
Metabolon	US	12/327,758	Granted	12/3/2008	US 7,884,318	2/8/2011	7/18/2029
Metabolon	JP	2009-529349	Granted	3/18/2009	JP 5,297,379	6/21/2013	9/18/2027
Metabolon	CH	7842724.2	Validated	3/23/2009	EP 2,061,899	8/29/2012	9/18/2027
Metabolon	DE	7842724.2	Validated	3/23/2009	EP 2,061,899	8/29/2012	9/18/2027
Metabolon	EP	7842724.2	Granted	3/23/2009	EP 2,061,899	8/29/2012	9/18/2027
Metabolon	FR	7842724.2	Validated	3/23/2009	EP 2,061,899	8/29/2012	9/18/2027
Metabolon	GB	7842724.2	Validated	3/23/2009	EP 2,061,899	8/29/2012	9/18/2027
Metabolon	IE	7842724.2	Validated	3/23/2009	EP 2,061,899	8/29/2012	9/18/2027
Metabolon	JP	2009-532611	Granted	4/10/2009	JP 5,363,984	9/13/2013	10/12/2027
Metabolon/ Cornell	US	12/463,690	Granted	5/11/2009	US 7,947,453	5/24/2011	4/13/2021
Metabolon/ Duke Univ.	US	12/300,000	Granted	5/27/2009	US 8,394,354	3/12/2013	9/19/2029
Metabolon	HK	9110580.6	Granted	11/12/2009	HK 1131209	11/27/2015	8/8/2027
Metabolon	HK	9110767.1	Granted	11/17/2009	HK 1,131,806	12/14/2012	9/18/2027
Metabolon	CH	8780229.4	Validated	12/8/2009	CH 2,164,977	10/30/2013	7/17/2028
Metabolon	DE	8780229.4	Validated	12/8/2009	DE 2,164,977	10/30/2013	7/17/2028
Metabolon	EP	8780229.4	Granted	12/8/2009	EP 2,164,977	10/30/2013	7/17/2028
Metabolon	ES	8780229.4	Validated	12/8/2009	EP 2,164,977	10/30/2013	7/17/2028
Metabolon	FR	8780229.4	Validated	12/8/2009	EP 2,164,977	10/30/2013	7/17/2028
Metabolon	GB	8780229.4	Validated	12/8/2009	GB 2,164,977	10/30/2013	7/17/2028
Metabolon	HK	10109028.5	Granted	12/8/2009	HK 1142636	3/28/2014	7/17/2028
Metabolon	IE	8780229.4	Validated	12/8/2009	IE 2,164,977	10/30/2013	7/17/2028
Metabolon	SG	PCT/US2008/008756	Granted	12/17/2009	SG 157,785	7/13/2012	12/17/2029
Metabolon	AU	AU 2008279778	Granted	1/14/2010	AU 2008279778	1/8/2015	7/17/2028
Metabolon	MX	MX/a/2010/000414	Granted	1/14/2010	MX 315,308	11/13/2013	1/14/2030
Metabolon	JP	2010-517019	Granted	1/15/2010	JP 5,701,601	2/27/2015	7/17/2028
Metabolon	US	12/441,945	Granted	2/12/2010	US 8,518,650	8/27/2013	9/18/2027
Metabolon/ Univ. Michigan	JP	2010-521202	Granted	2/14/2010	JP 5,406,187	11/8/2013	8/15/2028
Metabolon/ Univ. Michigan	DE	8827819.7	Validated	2/18/2010	EP 2,179,292	11/28/2012	8/15/2028

Applicant / Owner	Country	Application No.	Status	Filing Date	Parent No.	Issue Date	Expiration Date
Metabolon/ Univ. Michigan	EP	8827819.7	Granted	2/18/2010	EP 2,179,292	11/28/2012	8/15/2028
Metabolon/ Univ. Michigan	GB	8827819.7	Validated	2/18/2010	EP 2,179,292	11/28/2012	8/15/2028
Metabolon/ Univ. Michigan	AU	2008289172.0	Granted	3/11/2010	AU 2,008,289,172	5/2/2013	8/15/2028
Metabolon	JP	2010-532284	Granted	4/28/2010	JP 5,270,684	5/17/2013	10/31/2028
Metabolon	JP	2010-543261	Granted	7/15/2010	JP 5,512,546	4/4/2014	1/15/2029
Metabolon	CN	200980109140.X	Granted	8/1/2010	ZL2009801091 40.x	6/25/2014	1/15/2029
Metabolon/ Univ. Michigan	HK	10110005.0	Granted	10/22/2010	HK 1,143,418	8/16/2013	8/15/2028
Metabolon/ Mass Gen Hospital	US	13/082,843	Granted	4/8/2011	US 8,679,457	3/25/2014	4/8/2031
Metabolon	US	13/084,999	Granted	4/12/2011	US 8,175,816	5/8/2012	8/7/2026
Metabolon	JP	2011-549293	Granted	8/5/2011	JP 5,567,600	6/27/2014	2/5/2030
Metabolon	US	13/148,082	Granted	8/5/2011	US 8,658,351	2/25/2014	8/5/2031
Metabolon	CH	10739188.0	Validated	9/5/2011	EP 2,393,946	12/4/2013	9/5/2031
Metabolon	DE	10739188.0	Validated	9/5/2011	EP 2,393,946	12/4/2013	9/5/2031
Metabolon	EP	10739188.0	Granted	9/5/2011	EP 2,393,946	12/4/2013	9/5/2031
Metabolon	FR	10739188.0	Validated	9/5/2011	EP 2,393,946	12/4/2013	9/5/2031
Metabolon	GB	10739188.0	Validated	9/5/2011	EP 2,393,946	12/4/2013	9/5/2031
Metabolon	US	13/431,126	Granted	3/27/2012	US 9,189,595	11/17/2015	9/27/2032
Metabolon	JP	JP2012-532349	Granted	3/28/2012	JP 5,866,287	1/8/2016	10/1/2030
Metabolon	US	13/457,620	Granted	4/27/2012	US 8,546,098	10/1/2013	7/26/2028
Metabolon	CH	12188223.7	Validated	10/11/2012	CH 2,546,649	2/25/2015	10/31/2028
Metabolon	DE	12188223.7	Validated	10/11/2012	DE 2,546,649	2/25/2015	10/31/2028
Metabolon	EP	12188223.7	Granted	10/11/2012	EP 2,546,649	2/25/2015	10/31/2028
Metabolon	FR	12188223.7	Validated	10/11/2012	FR 2,546,649	2/25/2015	10/31/2028
Metabolon	GB	12188223.7	Validated	10/11/2012	GB 2,546,649	2/25/2015	10/31/2028
Metabolon/ East Virginia Medical School	US	13/698,116	Granted	11/15/2012	US 8,980,548	3/17/2015	1/27/2033
Metabolon/ Univ. Michigan	EP	12194382.3	Granted	11/27/2012	EP 2,597,464	2/25/2015	8/15/2028
Metabolon	MX	MX/a/2013/008169	Granted	7/12/2013	MX 341,954	9/8/2016	7/17/2028
Metabolon	US	13/966,475	Granted	8/14/2013	US 8,809,008	8/19/2014	7/26/2028

Applicant / Owner	Country	Application No.	Status	Filing Date	Parent No.	Issue Date	Expiration Date
Metabolon / Helmholtz Centrum	US	14/128,107	Granted	12/20/2013	US 9,109,252	8/18/2015	6/21/2032
Metabolon	JP	2014-530734	Granted	3/13/2014	JP 6,158,186	6/16/2017	9/11/2032
Metabolon	US	14/324,689	Granted	7/7/2014	US 9,250,225	2/2/2016	7/17/2028
Metabolon	AU	2014216035.0	Granted	8/29/2014	AU 2014216035	12/22/2016	7/17/2028
Metabolon	JP	2014-218116	Granted	10/27/2014	JP 5,876,918	1/29/2016	7/17/2028
Metabolon	EP	12196378.90	Granted	8/8/2007	EP 2,607,902	10/4/2017	10/8/2027
Metabolon	DE	12196378.90	Validated	8/8/2007	EP 2,607,902	10/4/2017	10/8/2027
Metabolon	FR	12196378.90	Validated	8/8/2007	EP 2,607,902	10/4/2017	10/8/2027
Metabolon	GB	12196378.90	Validated	8/8/2007	EP 2,607,902	10/4/2017	10/8/2027
Metabolon	IE	12196378.90	Validated	8/8/2007	EP 2,607,902	10/4/2017	10/8/2027
Metabolon	CH	12107388.90	Validated	8/8/2007	EP 2,607,902	10/4/2017	10/8/2027
Metabolon	EP	12807813.6	Granted	1/31/2014	EP 2,726,636	1/3/2018	1/31/2034
Metabolon	CH	12807813.6	Validated	1/31/2014	EP 2,726,636	1/3/2018	1/31/2034
Metabolon	DE	12807813.6	Validated	1/31/2014	EP 2,726,636	1/3/2018	1/31/2034
Metabolon	FR	12807813.6	Validated	1/31/2014	EP 2,726,636	1/3/2018	1/31/2034
Metabolon	GB	12807813.6	Validated	1/31/2014	EP 2,726,636	1/3/2018	1/31/2034
Metabolon	EP	EP 15155591.9	Granted	2/18/2015	EP 2,939,512B	1/31/2018	10/31/2028
Metabolon	CH	EP 15155591.9	Allowed	2/18/2015	EP 2,939,512B		
Metabolon	DE	EP 15155591.9	Allowed	2/18/2015	EP 2,939,512B		
Metabolon	FR	EP 15155591.9	Allowed	2/18/2015	EP 2,939,512B		
Metabolon	GB	EP 15155591.9	Allowed	2/18/2015	EP 2,939,512B		
Metabolon	IE	EP 15155591.9	Allowed	2/18/2015	EP 2,939,512B		
Metabolon	US	15/315,147	Granted	11/30/2016	US 9,892,895	2/13/2018	11/30/2036
Metabolon	US	14/763,962	Granted	7/28/2015	US 9,910,047	03/06/2018	07/28/2035
Metabolon	EP	14746017.4	Granted	7/8/2015	EP 2,951,313	3/07/2018	07/08/2035
Metabolon	CH	14746017.4	Allowed	7/8/2015			
Metabolon	DE	14746017.4	Allowed	7/8/2015			
Metabolon	FR	14746017.4	Allowed	7/8/2015			
Metabolon	GB	14746017.4	Allowed	7/8/2015			
Metabolon	IE	14746017.4	Allowed	7/8/2015			
Metabolon	EP	7758894.5	Published	3/20/2007			
Metabolon	CA	20072662987	Published	8/8/2007			
Metabolon	BR	PI0815095-8	Published	7/17/2008			
Metabolon	CA	2,690,541	Published	7/17/2008			
Metabolon	CA	2,712,455	Pending	1/15/2009			
Metabolon	US	12/376,903	Published	6/1/2010			
Metabolon	EP	9702007.7	Published	7/19/2010			
Metabolon	BR	PI1013387-09	Pending	9/20/2011			
Metabolon	EP	10774032.6	Published	4/30/2012			
Metabolon	US	13/800,010	Published	3/13/2013			
Metabolon	US	14/344,655	Published	3/13/2014			
Metabolon	EP	12831223.8	Published	3/18/2014			

Applicant / Owner	Country	Application No.	Status	Filing Date	Parent No.	Issue Date	Expiration Date
Metabolon	JP	2015-556042	Pending	7/30/2015			
Metabolon	WO	PCT/US2015/042904	Expired	7/30/2015			1/30/2017
Metabolon	US	14/843,356	Published	9/2/2015			
Metabolon	US	14/856,184	Published	9/16/2015			
Metabolon	CA	2,911,204	Pending	11/2/2015			
Metabolon	WO	PCT/US2015/058934	Expired	11/4/2015			5/5/2017
Metabolon	US	14/889,930	Published	11/9/2015			
Metabolon	BR	BR112015028253-9	Published	11/10/2015			
Metabolon	MX	MX/a/2015/015561	Pending	11/10/2015			
Metabolon	CN	201480027332.7	Published	11/13/2015			
Metabolon	JP	2016-514016	Pending	11/13/2015			
Metabolon	WO	PCT/US2015/061215	Expired	11/18/2015			5/19/2017
Metabolon	US	14/948,457	Published	11/23/2015			
Metabolon	JP	2015-236454	Pending	12/3/2015			
Metabolon	AU	2014265669	Pending	12/7/2015			
Metabolon	EP	14797070.1	Published	12/14/2015			
Metabolon	US	14/975,988	Published	12/21/2015			
Metabolon	WO	PCT/US2016/016536	Expired	2/4/2016			8/6/2017
Metabolon	US	15/026,341	Published	3/31/2016			
Metabolon	HK	16104033.3	Published	4/8/2016			
Metabolon	HK	16105395.2	Published	5/11/2016			
Metabolon	AU	2014364539	Pending	5/27/2016			
Metabolon	US	62/344,613	Expired	6/2/2016			6/2/2017
Metabolon	EP	14870759.9	Published	6/3/2016			
Metabolon	HK	16106343.3	Published	6/3/2016			
Metabolon	SG	11201604702Y	Pending	6/9/2016			
Metabolon	CA	2,933,571	Pending	6/10/2016			
Metabolon	US	15/104,560	Published	6/15/2016			
Metabolon	JP	2016-541152	Pending	6/17/2016			
Metabolon	MX	MX/a/2016/008045	Pending	6/17/2016			
Metabolon	MX	MX/a/2016/009020	Pending	7/8/2016			
Metabolon	AU	AU2016206265	Published	7/19/2016			
Metabolon	US	62/367,839	Expired	7/28/2016			7/28/2017
Metabolon	US	15/251,579	Published	8/30/2016			
Metabolon	HK	16110994.7	Published	9/19/2016			
Metabolon	CA	2,945,165	Pending	10/6/2016			
Metabolon	JP	JP 2016-561615	Published	10/7/2016			
Metabolon	US	15/288,917	Published	10/7/2016			
Metabolon	AU	AU2015243857	Pending	10/8/2016			
Metabolon	EP	15721065.9	Published	10/18/2016			
Metabolon	WO	PCT/US2016/060245	Published	11/3/2016			5/3/2018
Metabolon	HK	16113151	Published	11/16/2016			
Metabolon	JP	2016-569423	Pending	11/24/2016			

Applicant / Owner	Country	Application No.	Status	Filing Date	Parent No.	Issue Date	Expiration Date
Metabolon	CN	201580030719.2	Published	12/8/2016			
Metabolon	US	62/435,967	Expired	12/19/2016			12/19/2017
Metabolon	EP	EP15729638.5	Published	12/21/2016			
Metabolon	CA	2955204	Pending	1/13/2017			
Metabolon	CN	201580040519.5	Published	1/25/2017			
Metabolon	AU	2015296304	Published	1/30/2017			
Metabolon	JP	JP2017-505546	Pending	1/30/2017			
Metabolon	EP	15827995	Published	2/28/2017			
Metabolon	US	62/479,534	Expired	3/31/2017			3/31/2018
Metabolon	US	62/487,542	Expired	4/20/2017			4/20/2018
Metabolon	CA	2,965,874	Pending	4/25/2017			
Metabolon	JP	2017-526884	Pending	5/18/2017			
Metabolon	US	15/523,854	Pending	5/2/2017			
Metabolon	EP	15856657.0	Published	5/10/2017			
Metabolon	EP	15860608.8	Published	5/16/2017			
Metabolon	CN	201580062017.2	Published	5/16/2017			
Metabolon	CN	201580063349.2	Published	5/19/2017			
Metabolon	US	15/527,362	Published	5/17/2017			
Metabolon	WO	PCT/US2017/034605	Published	5/26/17			12/2/2018
Metabolon	US	62/512,776	Pending	5/31/17			5/31/2018
Metabolon	US	62/526,043	Pending	6/28/2017			6/28/2018
Metabolon	WO	PCT/US2017/044151	Published	7/27/17			7/27/2018
Metabolon	CA	2,976,052	Pending	8/4/2017			
Metabolon	CN	201680020275.9	Published	9/29/2017			
Metabolon	EP	16715645.4	Pending	8/9/2017			
Metabolon	JP	2017-541232	Pending	8/4/2017			
Metabolon	US	15/548,854	Published	8/4/2017			
Metabolon	EP	16715645.4	Pending	8/9/2017			
Metabolon	US	62/558,014	Pending	9/13/2017			9/13/2018
Metabolon	US	62/558,415	Pending	9/14/2017			9/14/2018
Metabolon	US	62/564,558	Pending	9/28/2017			9/29/2018
Metabolon	EP	17194611.4	Published	10/03/2017			
Metabolon	US	62/570,308	Pending	10/10/2017			10/10/2018
Metabolon	US	62/592,639	Pending	11/30/2017			11/30/2018
Metabolon	US	62/599,403	Pending	12/15/2017			12/15/2018
Metabolon	WO	PCT/US2017/066364	Pending	12/14/2017			6/19/2019
Metabolon	US	15/872,373	Pending	1/16/2018			
Metabolon	WO	PCT/US2018/024767	Pending	3/28/2018			9/30/2019
Metabolon	US	62/652,346	Pending	4/4/2018			4/4/2019
Metabolon	WO	PCT/US2018/027734	Pending	4/16/2018			10/20/2019

EXHIBIT C

Trademarks

SEE ATTACHED

Intellectual Property Schedule

Trademarks (All Marks are Owned Solely by Metabolon, Inc.):

Type of IP: Trademark	Country	Status	Application Number	Registration Number	Application Date	Registration Date
Precision Metabolomics	Int'l- Madrid Protocol	Pending	A0067091		5/16/2017	
Precision Metabolomics	Int'l- Madrid Protocol UK	Registered (UK)	A0067091	1356888	5/16/2017	10/24/17
Precision Metabolomics	US	Pending	87/438,891		5/5/2017	
accuGFR	US	Pending	A0065526		3/9/2017	
accuGFR	Int'l- Madrid Protocol	Pending	1 348 028		3/9/2017	
LIPOMICS	US	Registered	86400298	4746986	9/19/2014	6/2/2015
Lipomics Logo	US	Registered	86400276	4727737	9/19/2014	4/28/2015
META IMD	US	Pending/Statement of Use Accepted	87192130		10/4/2016	
META IMD	Argentina	Pending	3.617.981		6/30/2017	
META IMD	Brazil	Pending	912966815		6/30/17	
META IMD	Chile	Pending	1261929		7/24/17	
META IMD	Peru	Registered	708373	253734	7/5/2017	8/22/2017
META IMD	Qatar	Pending	116429			
META IMD	Saudi Arabia	Awaiting filing receipt				
META IMD	Int'l- Madrid Protocol	Pending	A0067599		6/7/2017	
META IMD	Int'l- Madrid Protoco/ Columbial	Registered	15665.105	1361969	6/7/2017	4/18/2018
META IMD	Int'l- Madrid Protoco/ Germany	Registered	15665.105	1361969	6/7/2017	1/31/2018
META IMD	Int'l- Madrid Protoco/ Spain	Registered	15665.105	1361969	6/7/2017	1/19/2018
META IMD	Int'l- Madrid Protocol (Benelux)	Registered (Benelux)	A0067599	1361969	6/7/2017	11/8/17
METABOLON	US	Registered	78561330	3,058,960	2/5/2005	2/14/2006
METABOLON & Design	US	Registered	77443519	3,530,800	4/9/2008	11/11/2008

Type of IP- Trademark	Country	Status	Application Number	Registration Number	Application Date	Registration Date
METABOLON Metaboman Design	Int'l- Madrid Protocol Only	Registered	A0046136	1242182	11/3/2014	4/9/2015
METABOLON Metaboman Design	Japan	Registered	A0046136	1242182	11/3/2014	4/9/2015
METABOLON Metaboman Design	Mexico	Registered	A0046136	1242182	11/3/2014	4/9/2015
METABOLON Metaboman Design	US	Registered	86442915	4814724	11/3/2014	9/15/2015
METABOLON PLUS DESIGN (SPHERE)	Canada	Registered	1390597	TMA7930994	4/9/2008	3/28/2011
METABOLON PLUS DESIGN (SPHERE)	Int'l- Madrid Protocol Only	Registered	A0012140	78675	4/18/2008	4/18/2008
METABOLON PLUS DESIGN (SPHERE)	Mexico	Registered				
METABOLYNC & Design	Austria	Registered	A0046148	124978	11/4/2014	11/4/2014
METABOLYNC & Design	Germany	Registered	A0046148	124978	11/4/2014	11/4/2014
METABOLYNC & Design	Int'l- Madrid Protocol Only	Registered	A0046148	124978	11/4/2014	11/4/2014
METABOLYNC & Design	Japan	Registered	A0046148	124978	11/4/2014	11/4/2014
METABOLYNC & Design	Mexico	Registered	A0046149	124979	11/4/2014	11/4/2014
METABOLYNC & Design	Switzerland	Registered	A0046150	124980	11/4/2014	11/4/2014
METABOLYNC & Design	United Kingdom	Registered	A0046151	124981	11/4/2014	11/4/2014
METABOLYNC & Design	US	Registered	86442918	4801218	11/3/2014	8/25/2015
QUINTASA-Petition to Cancel (owned by Ferring B.V.)	Ferring/US	Registered	76681820	4159546	9/13/2007	7/10/2012
QUANTOSE	Benelux	Registered	A0053483	1278334	9/29/2015	9/29/2015
QUANTOSE	China	Registered	85468464	1278334	3/19/2017	
QUANTOSE	Denmark	Registered	A0053483	1278334	9/29/2015	9/29/2015
QUANTOSE	Germany	Registered	A0053483	1278334	9/29/2015	9/29/2015
QUANTOSE	Int'l- Madrid Protocol Only	Registered	A0053483	1278334	9/29/2015	9/29/2015
QUANTOSE	Switzerland	Registered	A0053483	1278334	9/29/2015	11/14/2016
QUANTOSE	Japan	Registered	A0053483	1278334	9/29/2015	9/29/2015
QUANTOSE	Norway	Registered	A0053483	1278334	9/29/2015	9/29/2015
QUANTOSE	US	Registered	85768464	4956087	11/9/2011	5/10/2016

Type of IP: Trademark	Country	Status	Application Number	Registration Number	Application Date	Registration Date
QUANTOSE	Sweden	Registered	A0053483	1278334	9/29/2015	12/7/16
TRUEMASS	US	Registered	86400285	4727739	9/19/2014	4/28/2015